Nemesis Bioscience Ltd announced today that it had reached an agreement on terms for a two-year research collaboration with Shionogi & Co. Ltd. to further develop Nemesis Transmid Technology© for the treatment and/or prevention of hard-to-treat respiratory infections caused by Pseudomonas aeruginosa. The collaboration will leverage the innovative science and technology platforms of both parties
Nemesis Bioscience has been successful in winning a £414, 000 award granted by the UK’s innovation agency, Innovate UK. The Small Business Research Initiative (SBRI)
Nemesis Bioscience today announced the expansion of its presence in Aberystwyth by opening a new pre-clinical development facility at the University. Having become members at
New Chairman Brings “Wealth of Experience” to Pioneering Biotech Firm Simon Sturge, Executive Vice President of Business, Operations and Strategy at Merck Healthcare, is today confirmed as
PHOTO: From Left: Prof Conrad Lichtenstein (Nemesis CSO), Dr Frank Massam (Nemesis CEO), Dr Takeshi Shiota (Shionogi SVP, Pharmaceutical Research Division) and Dr Kai Stoeber
Nemesis Bioscience today announced the appointment of Dr Mark McCamish as Scientific Advisor for the development of its suite of Bacterial Cybergenetics© technologies. These include
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000, and the commencement of
Nemesis Bioscience today announced the appointment of Dr Alastair Riddell as non-executive Chairman. The appointment is effective from the 1st July and will bring Alastair’s
Nemesis Bioscience has beaten tough competition from across the country to win a place to showcase its product at the UK’s largest innovation show in
Nemesis Bioscience Ltd (Cambridge, UK) announced today that it has received a funding award from the UK’s innovation agency, Innovate UK. The Smart Award will be used to develop and protect a novel method for the delivery of polynucleotides, including therapeutics, into bacteria. Nemesis Bioscience Ltd has invented, developed and protected a family of novel biological